Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Mohamad Moussa, Lazaros Lazarou, Athanasios Dellis, Mohamed Abou Chakra & Athanasios Papatsoris. (2021) An up-to-date evaluation of darolutamide for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 22:4, pages 397-402.
Read now
Read now
Ruby Gupta, Iris Y Sheng, Pedro C. Barata & Jorge A. Garcia. (2020) Non-metastatic castration-resistant prostate cancer: current status and future directions. Expert Review of Anticancer Therapy 20:6, pages 513-522.
Read now
Read now
Athanasios E. Dellis & Athanasios G. Papatsoris. (2019) Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy 20:2, pages 163-172.
Read now
Read now
Marcello Tucci, Clizia Zichi, Consuelo Buttigliero, Francesca Vignani, Giorgio V Scagliotti & Massimo Di Maio. (2018) Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. OncoTargets and Therapy 11, pages 7353-7368.
Read now
Read now
Athanasios E. Dellis & Athanasios G. Papatsoris. (2018) Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. Expert Opinion on Investigational Drugs 27:6, pages 553-559.
Read now
Read now
Articles from other publishers (44)
Aniekan E. Owen, Emmah I. Ime, Elizabeth N. Mbim, Henry O. Edet, Innocent Benjamin, Grace I. Iniama, Uwem O. Edet, Amanda-Lee E. Manicum & Hitler Louis. (2023) Exploring the anticancer potential of sulfate-hydroxy-butanone derivatives: insights from experimental and quantum chemical investigations. Zeitschrift für Physikalische Chemie 0:0.
Crossref
Crossref
Xiujin Chang, Di Zhang, Fangui Qu, Youquan Xie, Tian Chen, Yuqing Zhang, Qianming Du, Jinlei Bian, Zhiyu Li, Jubo Wang & Xi Xu. (2023) Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer. European Journal of Medicinal Chemistry 257, pages 115490.
Crossref
Crossref
Emeline Colomba, Sarah Flora Jonas, Jean-Christophe Eymard, Rémi Delva, Pierre Emmanuel Brachet, Yann Neuzillet, Nicolas Penel, Guilhem Roubaud, Emmanuelle Bompas, Hakim Mahammedi, Raffaelle Longo, Carole Helissey, Philippe Barthélemy, Delphine Borchiellini, Ali Hasbini, Franck Priou, Carolina Saldana, Eric Voog, Bérangère Narcisso, Sylvain Ladoire, Jean-François Berdah, Jean-Baptiste Aisenfarb, Stéphanie Foulon & Karim Fizazi. (2023) A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA. European Urology.
Crossref
Crossref
Brent Cao, Melissa Kim, Natalie M. Reizine & Daniel M. Moreira. (2023) Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. European Urology Oncology 6:3, pages 237-250.
Crossref
Crossref
Elisabetta Tortorella, Sabrina Giantulli, Alessandro Sciarra & Ida Silvestri. (2023) AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways. International Journal of Molecular Sciences 24:3, pages 2046.
Crossref
Crossref
Greg Van-Duyne, Ian A. Blair, Cynthia Sprenger, Vera Moiseenkova-Bell, Stephen Plymate & Trevor M. Penning. 2023. Hormone Receptors: Structures and Functions. Hormone Receptors: Structures and Functions
439
481
.
Ioannis Avgeris, Dimanthi Pliatsika, Sotiris S. Nikolaropoulos & Manolis A. Fousteris. (2022) Targeting androgen receptor for prostate cancer therapy: From small molecules to PROTACs. Bioorganic Chemistry 128, pages 106089.
Crossref
Crossref
Changwei Chen, Xin Chai, Xueping Hu, Shengying Lou, Dan Li, Tingjun Hou & Sunliang Cui. (2022)
Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1
H
-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor
. Journal of Medicinal Chemistry 65:19, pages 13074-13093.
Crossref
Crossref
M. S. Rahnama’i. (2022) Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic. American Journal of Men's Health 16:4, pages 155798832211155.
Crossref
Crossref
Yundong He, Weidong Xu, Yu-Tian Xiao, Haojie Huang, Di Gu & Shancheng Ren. (2022) Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Fabrizio Fontana, Martina Anselmi & Patrizia Limonta. (2022) Molecular mechanisms and genetic alterations in prostate cancer: From diagnosis to targeted therapy. Cancer Letters 534, pages 215619.
Crossref
Crossref
Kazuhiro Suzuki, Vince Grillo, Yirong Chen, Shikha Singh & Dianne Athene Ledesma. (2021) Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective. JCO Global Oncology:7, pages 302-310.
Crossref
Crossref
Faiza Naseer, Tahir Ahmad, Kousain Kousar & Sadia Anjum. (2021) Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma. Frontiers in Pharmacology 12.
Crossref
Crossref
Caibin Fan, Wei Lu, Kai Li, Chunchun Zhao, Fei Wang, Guanxiong Ding & Jianqing Wang. (2021) Identification of immune cell infiltration pattern and related critical genes in metastatic castration-resistant prostate cancer by bioinformatics analysis. Cancer Biomarkers 32:3, pages 363-377.
Crossref
Crossref
Simrit Safarulla, Pritisha S. Khillar, Sudarshan Kini & Amit Kumar Jaiswal. (2021) Tissue engineered scaffolds as 3D models for prostate cancer metastasis to bone. Materials Today Communications 28, pages 102641.
Crossref
Crossref
Xiaotian Kong, Enming Xing, Tony Zhuang, Pui-Kai Li & Xiaolin Cheng. (2021) Mechanistic Insights into the Allosteric Inhibition of Androgen Receptors by Binding Function 3 Antagonists from an Integrated Molecular Modeling Study. Journal of Chemical Information and Modeling 61:7, pages 3477-3494.
Crossref
Crossref
Neeraj K. Saini, Bhavesh B. Gabani, Umesh Todmal, Suresh P. Sulochana, Vinay Kiran, Mohd. Zainuddin, Narayanan Balaji, Sai B. Polina, Nuggehally R. Srinivas & Ramesh Mullangi. (2021) Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients. Drug Metabolism Letters 14:1, pages 54-65.
Crossref
Crossref
Jana Kvízová, Vladimíra Pavlíčková, Eva Kmoníčková, Tomáš Ruml & Silvie Rimpelová. (2021) Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions. Molecules 26:8, pages 2228.
Crossref
Crossref
Anna Maria Formenti, Alberto Dalla Volta, Luigi di Filippo, Alfredo Berruti & Andrea Giustina. (2021) Effects of Medical Treatment of Prostate Cancer on Bone Health. Trends in Endocrinology & Metabolism 32:3, pages 135-158.
Crossref
Crossref
Michał Wilk, Anna Waśko-Grabowska & Sebastian Szmit. (2020) Cardiovascular Complications of Prostate Cancer Treatment. Frontiers in Pharmacology 11.
Crossref
Crossref
Siva Nageswara Rao Gajula, Gangireddy Navitha Reddy, Dannarm Srinivas Reddy & Rajesh Sonti. (2020) Pharmacokinetic drug–drug interactions: an insight into recent US FDA-approved drugs for prostate cancer. Bioanalysis 12:22, pages 1647-1664.
Crossref
Crossref
Charles Ryan, Jeffrey S. Wefel & Alicia K. Morgans. (2019) A review of prostate cancer treatment impact on the CNS and cognitive function. Prostate Cancer and Prostatic Diseases 23:2, pages 207-219.
Crossref
Crossref
Lugeng He, Hui FangChao Chen, Yanqi WuYuyong Wang, Hongwei Ge, Lili WangYuehua WanHuadong He. (2020) Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. Medicine 99:15, pages e19760.
Crossref
Crossref
Xi Xu, Qianming Du, Ying Meng, Zhiyu Li, Hongxi Wu, Yan Li, Zhili Zhao, Raoling Ge, Xiaoyu Lu, Siqi Xue, Xijing Chen, Yong Yang, Jubo Wang & Jinlei Bian. (2020) Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists. European Journal of Medicinal Chemistry 192, pages 112196.
Crossref
Crossref
F. Kunath, P. J. Goebell, B. Wullich, D. Sikic & A. Kahlmeyer. (2019) Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review. World Journal of Urology 38:3, pages 601-611.
Crossref
Crossref
Sirin Saranyutanon, Sanjeev Kumar Srivastava, Sachin Pai, Seema Singh & Ajay Pratap Singh. (2019) Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope. Cancers 12:1, pages 51.
Crossref
Crossref
Claudia Ferroni & Greta Varchi. (2019) Non-Steroidal Androgen Receptor Antagonists and Prostate Cancer: A Survey on Chemical Structures Binding this Fast-Mutating Target. Current Medicinal Chemistry 26:33, pages 6053-6073.
Crossref
Crossref
Elisabeth Heath, Lance Heilbrun, Heather Mannuel, Glenn Liu, Primo Lara, J. Paul Monk, Thomas Flaig, Amado Zurita, Philip Mack, Ulka Vaishampayan, Philip Stella, Daryn Smith, Susan Bolton, Arif Hussain, Anas Al-Janadi, Daniel Silbiger, Muhammad Usman & S. Percy Ivy. (2019) Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. The Oncologist 24:9, pages 1149-e807.
Crossref
Crossref
Tatsuo Sugawara, Simon J. Baumgart, Ekaterina Nevedomskaya, Kristin Reichert, Holger Steuber, Pascale Lejeune, Dominik Mumberg & Bernard Haendler. (2019) Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models. International Journal of Cancer 145:5, pages 1382-1394.
Crossref
Crossref
E. David Crawford, Axel Heidenreich, Nathan Lawrentschuk, Bertrand Tombal, Antonio C. L. Pompeo, Arturo Mendoza-Valdes, Kurt Miller, Frans M. J. Debruyne & Laurence Klotz. (2018) Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer and Prostatic Diseases 22:1, pages 24-38.
Crossref
Crossref
Sigfred Ian R. Alpajaro, Jerad A. K. Harris & Christopher P. Evans. (2018) Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies. Prostate Cancer and Prostatic Diseases 22:1, pages 16-23.
Crossref
Crossref
Martina Pagliuca, Carlo Buonerba, Karim Fizazi & Giuseppe Di Lorenzo. (2019) The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer. Drugs 79:4, pages 381-400.
Crossref
Crossref
Dong-Jin Hwang, Yali He, Suriyan Ponnusamy, Michael L. Mohler, Thirumagal Thiyagarajan, Iain J. McEwanRamesh Narayanan & Duane D. Miller. (2018) New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity. Journal of Medicinal Chemistry 62:2, pages 491-511.
Crossref
Crossref
R. A. Gafanov, A. G. Dzidzaria, I. B. Kravtsov & S. V. Fastovets. (2019) Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. Cancer Urology 14:4, pages 139-149.
Crossref
Crossref
Simon Linder, Henk G van der Poel, Andries M Bergman, Wilbert Zwart & Stefan Prekovic. (2019) Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocrine-Related Cancer 26:1, pages R31-R52.
Crossref
Crossref
Joelle El-Amm & Jeanny B Aragon-Ching. (2019) The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology 13, pages 117955491983392.
Crossref
Crossref
Harsh Shah & Ulka Vaishampayan. (2018) Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. Targeted Oncology 13:6, pages 679-689.
Crossref
Crossref
Yuki Kita, Takayuki Goto, Shusuke Akamatsu, Toshinari Yamasaki, Takahiro Inoue, Osamu Ogawa & Takashi Kobayashi. (2018) Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges. Cancers 10:10, pages 345.
Crossref
Crossref
Madeline Cancian & Joseph F. RenzulliIIII. (2018) Nonmetastatic Castration-resistant Prostate Cancer: A Modern Perspective. Urology 116, pages 13-16.
Crossref
Crossref
Ekaterina Nevedomskaya, Simon Baumgart & Bernard Haendler. (2018) Recent Advances in Prostate Cancer Treatment and Drug Discovery. International Journal of Molecular Sciences 19:5, pages 1359.
Crossref
Crossref
Andrew W. HahnCelestia S. HiganoMary-Ellen TaplinCharles J. RyanNeeraj Agarwal. (2018) Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. American Society of Clinical Oncology Educational Book:38, pages 363-371.
Crossref
Crossref
Theodore Gourdin. (2018) Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions. Current Opinion in Oncology 30:3, pages 159-164.
Crossref
Crossref
Andrew W. Hahn, Peter Hale, Nityam Rathi & Neeraj Agarwal. (2017) Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. Current Opinion in Urology 27:6, pages 559-565.
Crossref
Crossref
Di Zhang, Tian Chen, Yuqing Zhang, Yan Li, Min Wang, Hongxi Wu, Zhixia Qiu, Jinlei Bian, Zhiyu Li, Jubo Wang & Xi Xu. (2022) Discovery of Novel Thiohydantoin Derivatives as Full Antagonists and Efficient Degraders of Androgen Receptor. SSRN Electronic Journal.
Crossref
Crossref